Allergen Immunotherapy Portfolio

About Allergopharma

Allergopharma is a long-established, private German biotech focused exclusively on allergen immunotherapy (AIT), operating as a subsidiary of the publicly traded Dermapharm Group. The company is commercial-stage, with a portfolio of standardized allergy extracts for both diagnosis and subcutaneous/sublingual immunotherapy, targeting a broad range of respiratory and insect venom allergies. Its strategy is built on deep expertise in allergology, manufacturing quality, and a holistic approach to allergy management within the supportive infrastructure of a larger pharmaceutical group.

About Stallergenes Greer

Stallergenes Greer is a global leader in allergy therapeutics, focusing exclusively on allergen immunotherapy (AIT). The company leverages a fully integrated model spanning R&D, manufacturing, and commercialization to address a growing global allergy market. Its strategy centers on advancing precision medicine in AIT, expanding its geographic footprint, and broadening its portfolio through internal development and acquisitions, such as the recent purchase of ENTOMON S.R.L. to boost venom immunotherapy capacity.

Therapeutic Areas